- Home
- GWRS vs CRVS Comparison
GWRS vs CRVS Comparison
Compare GWRS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- CRVS
- Stock Information
- Founded
- GWRS 2003
- CRVS 2014
- Country
- GWRS United States
- CRVS United States
- Employees
- GWRS N/A
- CRVS N/A
- Industry
- GWRS Water Supply
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- CRVS Health Care
- Exchange
- GWRS Nasdaq
- CRVS Nasdaq
- Market Cap
- GWRS 268.4M
- CRVS 305.4M
- IPO Year
- GWRS 2010
- CRVS 2016
- Fundamental
- Price
- GWRS $10.03
- CRVS $5.55
- Analyst Decision
- GWRS
- CRVS Strong Buy
- Analyst Count
- GWRS 0
- CRVS 4
- Target Price
- GWRS N/A
- CRVS $15.00
- AVG Volume (30 Days)
- GWRS 64.9K
- CRVS 477.2K
- Earning Date
- GWRS 08-13-2025
- CRVS 08-07-2025
- Dividend Yield
- GWRS 3.12%
- CRVS N/A
- EPS Growth
- GWRS N/A
- CRVS N/A
- EPS
- GWRS 0.22
- CRVS N/A
- Revenue
- GWRS $54,270,000.00
- CRVS N/A
- Revenue This Year
- GWRS $8.31
- CRVS N/A
- Revenue Next Year
- GWRS $6.52
- CRVS N/A
- P/E Ratio
- GWRS $46.01
- CRVS N/A
- Revenue Growth
- GWRS 4.33
- CRVS N/A
- 52 Week Low
- GWRS $9.37
- CRVS $2.54
- 52 Week High
- GWRS $13.98
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- GWRS 52.21
- CRVS 69.70
- Support Level
- GWRS $9.65
- CRVS $5.03
- Resistance Level
- GWRS $9.96
- CRVS $5.81
- Average True Range (ATR)
- GWRS 0.26
- CRVS 0.32
- MACD
- GWRS 0.02
- CRVS 0.09
- Stochastic Oscillator
- GWRS 54.81
- CRVS 85.22
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).